AC
BMY icon

Abbrea Capital’s Bristol-Myers Squibb BMY Stock Holding History

Abbrea Capital’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,245
Closed -$284K – 229
2024
Q1 		$284K Sell
5,245
-599
-10% -$30.5K 0.04% 215
2023
Q4 		$300K Sell
5,844
-5,320
-48% -$279K 0.04% 201
2023
Q3 		$648K Buy
11,164
+165
+2% +$10.1K 0.1% 134
2023
Q2 		$703K Buy
10,999
+974
+10% +$65.3K 0.11% 135
2023
Q1 		$695K Buy
10,025
+150
+2% +$10.6K 0.12% 128
2022
Q4 		$711K Buy
9,875
+825
+9% +$62.2K 0.13% 126
2022
Q3 		$643K Sell
9,050
-252
-3% -$18.3K 0.12% 130
2022
Q2 		$721K Sell
9,302
-100
-1% -$7.62K 0.12% 131
2022
Q1 		$692K Buy
9,402
+255
+3% +$17.1K 0.1% 150
2021
Q4 		$570K Sell
9,147
-60
-0.7% -$3.52K 0.08% 160
2021
Q3 		$549K Sell
9,207
-1,315
-12% -$86.6K 0.08% 159
2021
Q2 		$703K Buy
10,522
+1,353
+15% +$88.2K 0.11% 139
2021
Q1 		$583K Buy
9,169
+980
+12% +$61K 0.1% 145
2020
Q4 		$512K Buy
8,189
+421
+5% +$25.9K 0.09% 147
2020
Q3 		$468K Buy
7,768
+892
+13% +$53.7K 0.1% 132
2020
Q2 		$404K Buy
6,876
+284
+4% +$17K 0.09% 145
2020
Q1 		$367K Buy
6,592
+493
+8% +$30.1K 0.1% 139
2019
Q4 		$392K Buy
+6,099
New +$349K 0.08% 145
2018
Q4 		– Sell
-4,738
Closed -$294K – 162
2018
Q3 		$294K Buy
4,738
+462
+11% +$27.4K 0.09% 150
2018
Q2 		$237K Buy
4,276
+12
+0.3% +$648 0.07% 156
2018
Q1 		$270K Buy
4,264
+145
+4% +$9.33K 0.09% 150
2017
Q4 		$252K Buy
4,119
+356
+9% +$22.3K 0.09% 140
2017
Q3 		$240K Buy
+3,763
New +$220K 0.09% 141

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Abbrea Capital's BMY Position: Q2 2024 in Review

Abbrea Capital sold out of Bristol-Myers Squibb (BMY) in Q2 2024, closing a stake of 5,245 shares — an estimated $284K sold.

Abbrea Capital first reported a position in BMY in Q3 2017 and held it in 23 quarters. The position peaked at $721K in Q2 2022. 2,148 funds tracked by Wall St. Rank hold BMY as of Q2 2024.

  • Abbrea Capital reported no remaining Bristol-Myers Squibb position as of Q2 2024 after selling out during the quarter.
  • Abbrea Capital sold 5,245 Bristol-Myers Squibb shares in Q2 2024, an estimated $284K.
  • Abbrea Capital first reported a position in Bristol-Myers Squibb in Q3 2017 and held it in 23 quarters.
  • Abbrea Capital's Bristol-Myers Squibb position peaked at $721K in Q2 2022.
  • 2,148 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2024.

Based on Abbrea Capital's 13F filing for Q2 2024, filed 8 Aug 2024.